Voriconazole is indicated for the treatment of serious invasive fungal infections, including invasive aspergillosis and candidemia in critically ill patients. Its major advantage is broad antifungal activity combined with excellent tissue and central nervous system penetration, making it highly effective even in difficult-to-treat infections. In ICU and oncology settings, where patients are immunocompromised, rapid initiation of effective antifungal therapy is crucial, and IV voriconazole ensures predictable plasma levels and reliable response. It is considered a first-line therapy in many international guidelines, especially for aspergillosis. Its ability to target life-threatening infections early significantly improves patient outcomes.